Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMS5552 in treatment-naïve type 2 diabetes mellitus (24-week efficacy, 52-week safety)
CTR20170473Phase 3Completed
- Sponsor
- Hua Medicine
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dorzagliatin in type 2 diabetes mellitus (T2DM), sponsored by Hua Medicine. Started May 2017; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20170473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170473.